Back to News
Market Impact: 0.1
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
Source: globenewswire.com
Patents & Intellectual Property
The article fragment says an additional five years of patent protection may be available through a standard extension. It provides no company, product, jurisdiction, or other details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Delaware jury awards Qualcomm $2 in damages, finds Arm breached license agreement
- ESA targets Anbernic emulation handhelds as "superfake" piracy enablers
- Disney offers $20M for Character.AI’s scandal-plagued chatbot tech
- US fines Bank of America $1.2bn for money laundering, sanctions violations
- Taiwan agrees to buy 30% of gas from Alaska LNG project, Trump says
- Oil rises amid growing Mideast tensions between Iran-backed Houthis and Saudi Arabia
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Search Earnings Call Transcripts With AI
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI